TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02823743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake
Study: NCT03837925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg Tablet
Description: Patient participation for 6 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patient participation for 6 weeks of treatment
Study: NCT03193346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sodium chloride 0.9 mg)
Description: Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
Study: NCT03371108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Glargine Injection
Description: Route of administration: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Route of administration: subcutaneous injection
Study: NCT00003750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Study: NCT03933917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution
Description: Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
Study: NCT00305006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Description: 90 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy (HABIT)
Description: 90 hours
Study: NCT02311855

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccine
Description: Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine.
Study: NCT03392077

Intervention type: OTHER
Intervention: No cervical dilatation
Description: after delivery of the baby cervix will be remain closed
Study: NCT02890667

Intervention type: OTHER
Intervention: Incident cancer
Description: The number of incident cancer cases
Study: NCT01050491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sitaxentan
Description: 100 mg once a day during one year. Bronchial fibroscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, one per day, during one year. Bronchial fibroscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, one per day, during one year. Bronchial fibroscopy
Study: NCT04161027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Pregabalin 75 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo capsule
Study: NCT00071396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
Study: NCT02447562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platform NOMHADchronic
Description: Intervention group with a health Platform NOMHADchronic

Intervention type: OTHER
Group type: OTHER
Intervention: Phone-based care group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Study: NCT01689168

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Tobacco cessation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Tobacco cessation counseling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: Full spine high velocity, low amplitude manipulation of the spine
Study: NCT00494455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcutaneous glucose monitoring
Description: continuous subcutaneous glucose monitoring for 72h

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcutaneous glucose monitoring
Description: continuous subcutaneous glucose monitoring for 72h
Study: NCT02606045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant von Willebrand factor
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant von Willebrand factor
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
Study: NCT02047227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris®
Description: Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GONAL-f®
Description: GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
Study: NCT02149875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dl-3-n-butylphthalide
Description: Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml saline intravenous infusion once daily for 10 days.
Study: NCT03144531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention for Kids and Parents (SKIP)
Description: Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
Study: NCT00753428

Intervention type: OTHER
Intervention: Community-based Survey
Description: Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults.
Study: NCT02252445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be administered.
Study: NCT00676741

Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03135340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General/regional anesthesia
Description: These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WALANT Injection
Description: 1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthetic Injection
Description: 0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
Study: NCT04789187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity-Interval-Training
Description: Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General Physical Activity Recommendations
Description: Patients will be given general physical activity recommendations during chemotherapy.
Study: NCT03581994

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DDI Test Report
Description: Test results of simulated patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DDI Test Report
Description: Test results of simulated patients
Study: NCT00516087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically modified CTLs
Description: LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2
Study: NCT02802462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT
Description: 3-minute intervals at 40% and 80%VO 2max
Study: NCT02394834

Intervention type: DRUG
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

Intervention type: DRUG
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT02802462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT
Description: sustained 60%VO 2max
Study: NCT04558684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Radiotherapy (5 Gy x 5 fractions)
Study: NCT03276988

Intervention type: DRUG
Group type: OTHER
Intervention: Period 1 GX-30, Period 2 THYROGEN®
Description: Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Period 1 THYROGEN®, Period 2 GX-30
Description: Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
Study: NCT00743899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The aggressive group
Description: Stents were implanted in lesions with diameter stenosis \>50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis \>50% and RD ≥2.0 mm and \<2.25 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The conservative group
Description: Stenting was performed only in lesions with diameter stenosis \>70% and reference diameter (RD) ≥2.25 mm
Study: NCT02031211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
Study: NCT02563951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS Spray 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS Spray 1.0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS Spray 2.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril 1mg (IV injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kytril 1mg (Tablet)
Study: NCT02751099

Intervention type: OTHER
Intervention: transplanted patients
Description: bone biopsy, echocardiogram, blood samples
Study: NCT03704311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
Study: NCT03452228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: Administered by Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by Intravenous (IV)
Study: NCT02699359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study: NCT01833988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal Bionic Pancreas
Description: Automated blood glucose control via a closed-loop bionic pancreas device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
Study: NCT05064410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
Study: NCT03671629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced clinical pharmacist service
Description: The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
Study: NCT00299182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
Study: NCT01693094

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them.
Study: NCT04352946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pre-Exposure Prophylaxis
Description: HCQ PreP 400mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets 400mg daily
Study: NCT04181320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Leg Ulcer Standard of Care with Granulox
Description: Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
Study: NCT04997915

Intervention type: OTHER
Intervention: Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU
Description: Critical COVID-19 patients admitted to the ICU
Study: NCT00904319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Power Training
Description: Aquatic power training program with an exercise specialist 2/week for 6 weeks.